Johnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus (SLE) disease activity in a Phase 2 study

BEERSE, BELGIUM , June 03, 2026 (GLOBE NEWSWIRE) -- Johnson & Johnson today announced nipocalimab met the primary endpoint of decreasing disease activity at 24 weeks as measured by SRI-4 b and continued to demonstrate sustained reduction in disease activity in adults with moderate-to-severe systemic lupus erythematosus (SLE) a through 52 weeks in the Phase 2 JASMINE study as measured by both SRI-4 b and LLDAS. c , 1 In addition, the study results showed greater response versus placebo plus background medication d in participants who tested positive for lupus-associated autoantibodies, which represents the vast majority (~80%) of people living with SLE. e , 1 These findings will be featured in a late-breaking presentation at the European Alliance of Associations for Rheumatology (EULAR) 2026 Congress in London and are among the 38 abstracts the Company is presenting across its Rheumatology portfolio.